An 8-week Open-Label Flexible-Dose Study Of Desvenlafaxine as Monotherapy In The Treatment Of Dysthymia
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2014
Price : $35 *
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Dysthymic disorder
- Focus Therapeutic Use
- 06 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 May 2014 Planned End Date changed from 1 Mar 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.